

Transapical approach



Transapical implantation. The catheter manipulation timeis about 20 minutes. Shorter operative time, loweroperative risk.

Minimal invasive surgery



Cardiopulmonary bypass is not required. Less trauma and complication Rapid post-operative recovery

Precisely capture leaflet

Smaller-sized delivery system (14F). Different size of devices can be provided for different mitral annular size and MR pattern.Multiple clips can be implanted for reducing residual MR.

Echo-guided Image



Hongyu Medical Technology Co., Ltd focuses on treatment of mitral regurgitation for pet canines

Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicated to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the selfdeveloped Mitral Valve Interventional Repair device V CLAMP. It is the only surgical instrument in the world that can be used to treat mitral regurgitation in pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.

Tel : 400 100 5433

- Add: Building 1, 3699 Yuanjiang Road, Minhang District, Shanghai, China
- **Email:** customer_service@hongyumedtech.com





MITRAL VALVE INTERVENTIONAL MEDICAL DEVICES

Focus on the treatment of pet cardiac disease

Company Profile



Shanghai Hongyu Medical Technology Co., LTD., is a high-tech enterprise dedicating to pet cardiology research, innovative medical device R&D and commercialization. Its core product is the self-developed mitral valve Interventional repair device V-CLAMP. It is the only surgical instrument around the world which can be used to treat mitral regurgitation for pet dogs. The company adheres to the concept of innovation and development, with the mission of benefiting the lives of pets.



V-CLAMP is currently in Hospitals and institutions in major cities at home and abroad have successively launched...

Preliminary Outcome of a Novel Edge-to-Edge Closure Device to Manage Mitral Regurgitation in Dogs Bo Liu¹, Stacey B. Leach², Wenzhi Pan³, Fangyu Zheng¹, Liujun Jia⁴, Xueying Zhou¹ and Background: Veterinary management of mitral valve regurgitation due to m alve disease in dogs is limited to medical treatments, which only postpones the onse of conceptus heart fail as or alignistics clinical memory. Most a mical removal use to manage this condition in humans require cardiopulmonary bypass and have a high ris of complications Animals: Eight dogs with naturally occurring mitral valve regurgitation OPEN ACCESS Methods: Prospective observational study. All dogs were treated with a nove Edinality edge-to-edge transcatheter device named ValveClamp. The total surgical procedural time and total catheterization time were recorded. Echocardiographic variable pre- and post-procedure were compared using Wilcoxin-signed rank test with a P < 0.05 dered significant. Data were expressed as median and interquartile ra absolute numbers and percentages. Results: The procedural success rate was 100% and all the doos survived ions. The median (interquartile range) total surgical procedural time was 86.5 (76-96.2) minutes and catheterization time was 23.5 (22-33.8) minutes. Echocardiography revealed a significant reduction in mitral regurgitation severity in all dogs following the procedure based on both a reduced mitral regurgitant maximum let area (P = 0.012) and a reduced mitral redurpitant maximum let area to left atria ana (P = 0.018). Conclusion: The ValveClamp device is effective at reducing the severity of mitra regurgitation in dogs with naturally occurring myxomatous valve disease nine mitted under men store deservation transmind when surner INTRODUCTION Mysonatious mitral valve disease (MMVD) is the most common cardiac disease in dogs, primarily discting small beeds (1). The standard care for this disease is primarily modical therapy, solid surgical treatment is performed in a misserity of dogs (2). Medical therapy postpores the rouse of congority beacht failure (OED), and also increases the survival time once CHU develop

Related reports

More cases

a frontiers

ry Science



Country: China Age: 11 Weight: 7.3KG MMVD:B2



Country: China Age: 9 Weight: 4KG MMVD:C



Country: China Age: 10 Weight: 9.1KG MMVD:C

Age: 12

MMVD:C



Age: 12 Weight: 10KG MMVD:C



Country: China Weight: 3.2KG



Country: China Age: 9 Weight: 5KG MMVD:D



Case report

" Datou ", an 8-year-old castrated male schnauzer weighting 8 kg was referred from Guangzhou to Shanghai XinYu Veterinary Cardiovascular Medical Center for further evaluation and treatment on January 8th, 2020. Datou was diagnosed with myxomatous mitral valve disease (stage D) and presented with severe mitral regurgitation and pulmonary hypertension, showed the clinical signs including panting, coughing, exercise intolerance, ascite, mild pulmonary edema and pericardial effusion. After discussion with the owner, the V-Clamp was chosen to perform the transcatheter mitral valve repair.

After the V-clamp repair surgery, there is a significantly reduction in mitral regurgitant volume and "Datou "showed a prominent improvement of cardiac function.











Pre-operative MR

Post-operative MR